| Style | Citing Format |
|---|---|
| MLA | Mortazavi SMJ, Najafi A, Toogeh G. "Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®)." Haemophilia, vol. 22, no. 5, 2016, pp. e451-e453. |
| APA | Mortazavi SMJ, Najafi A, Toogeh G (2016). Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®). Haemophilia, 22(5), e451-e453. |
| Chicago | Mortazavi SMJ, Najafi A, Toogeh G. "Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®)." Haemophilia 22, no. 5 (2016): e451-e453. |
| Harvard | Mortazavi SMJ, Najafi A, Toogeh G (2016) 'Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®)', Haemophilia, 22(5), pp. e451-e453. |
| Vancouver | Mortazavi SMJ, Najafi A, Toogeh G. Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®). Haemophilia. 2016;22(5):e451-e453. |
| BibTex | @article{ author = {Mortazavi SMJ and Najafi A and Toogeh G}, title = {Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®)}, journal = {Haemophilia}, volume = {22}, number = {5}, pages = {e451-e453}, year = {2016} } |
| RIS | TY - JOUR AU - Mortazavi SMJ AU - Najafi A AU - Toogeh G TI - Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®) JO - Haemophilia VL - 22 IS - 5 SP - e451 EP - e453 PY - 2016 ER - |